Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis
Chong, Lip Leong Soon, Yu Yang Soekojo, Cinnie Yentia Ooi, Melissa Chng, Wee Joo de Mel, Sanjay
Chong, Lip Leong
Soekojo, Cinnie Yentia
de Mel, Sanjay
Citations
Altmetric:
Alternative Title
Abstract
This study aims to evaluate the efficacy and safety of Daratumumab-based induction therapy (DBI) in newly diagnosed multiple myeloma (MM). We identified four eligible RCTs including 2735 patients. The primary outcomes of RCTs involving transplant eligible (TEMM) and non-transplant eligible MM (NTEMM) were stringent complete response (sCR) and progression-free survival (PFS) respectively. Meta-analysis was performed using random-effects models. DBI improved sCR rates for standard risk (SR) (OR 1.86, 95 % CI 1.41–2.46) but not HiR (high risk) (OR 0.78, 95 % CI 0.41–1.48) (interaction P = 0.01) TEMM. In NTEMM, DBI improved PFS in SR (HR 0.44, 95 % CI 0.35–0.55) but not HiR patients. (HR 0.81, 95 % CI 0.52–1.27) (interaction P = 0.02). In conclusion, while DBI is efficacious in SR patients, there is insufficient data to support a benefit in HiR-MM.
Keywords
Science & Technology, Life Sciences & Biomedicine, Oncology, Hematology, Daratumumab, Induction therapy, Newly diagnosed multiple myeloma, High cytogenetic risk, Meta-analysis
Source Title
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Publisher
ELSEVIER SCIENCE INC
Series/Report No.
Collections
Rights
Date
2021-03-01
DOI
10.1016/j.critrevonc.2020.103211
Type
Review